CompletedPhase 4

Ivermectin/ Permethrin for Scabies

Indonesia60 participantsStarted 2023-01-25

Plain-language summary

Scabies is a skin disease characterized by intense itching that worsens at night. It is very contagious, still has a high occurrence rate, and impacts patient quality of life. The use of scabicide followed by a clean and healthy lifestyle is the principle of scabies therapy. The primary treatment option for scabies is permethrin 5% cream. Ivermectin is an alternate treatment for scabies.

Who can participate

Age range6 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female * Age 6 years or above * Body weight 15kg or above * Clinical establishment of diagnosed scabies Exclusion Criteria: * Pregnant or breastfeeding woman * Scabies with secondary infection * Scabies with eczematization * History of receiving scabies treatment in the last four weeks * History of drug hypersensitivity

What they're measuring

The severity of scabetic lesions

Timeframe: 5 weeks

The severity of pruritus

Timeframe: 5 weeks

Trial details

NCT IDNCT05819983

SponsorUniversitas Padjadjaran

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-02-01

View on ClinicalTrials.gov More Scabies trials